Carmot Therapeutics, a Berkeley, CA-based clinical-stage biotechnology company, raised $150M in Series E funding.
The round was led by Deep Track Capital with participation from 5AM Ventures, Franklin Templeton, Frazier Life Sciences, Janus Henderson Investors, RA Capital Management, Millennium Management, TCGX, The Column Group, Venrock Healthcare Capital Partners and Willett Advisors.
The company intends to use the funds to strengthen its broad portfolio of clinical and preclinical assets designed to modulate gut hormones that are central to energy homeostasis.
Led by Heather Turner, Chief Executive Officer, Carmot Therapeutics is a clinical-stage biotechnology company that is focused on the discovery and development of disease-modifying therapies for people living with metabolic diseases including obesity and diabetes. The company uses Chemotype Evolution, a drug discovery platform, to identify novel incretin receptor signaling targets and develop a broad pipeline of therapeutics that have the potential to produce significant weight loss and improved glycemic control. It has three clinical candidates: CT-388 (once-weekly, dual GLP-1/GIP receptor modulator), CT-868 (once-daily, dual GLP-1/GIP receptor modulator) and CT-996 (oral, small molecule GLP-1 receptor agonist).
FinSMEs
31/05/2023